EcoDrugPlus

Protein Farnesyltransferase/geranylgeranyltransferase Type-1 Subunit Alpha-Like

Ensembl ID : ENSNBRG00000021692
Gene Symbol: LOC102797293
3 Cross references
221 Possible Orthologues:

Protein Kinase C Alpha Type-Like

Ensembl ID : ENSNBRG00000003773
Gene Symbol: LOC102782619
3 Cross references
213 Possible Orthologues:

Protein Kinase C Beta

Ensembl ID : ENSNBRG00000006882
Gene Symbol: PRKCB
4 Cross references
207 Possible Orthologues:

Protein Kinase C Beta Type-Like

Ensembl ID : ENSNBRG00000007763
Gene Symbol: LOC102789717
3 Cross references
223 Possible Orthologues:

Protein Kinase C Delta

Ensembl ID : ENSNBRG00000021535
Gene Symbol: PRKCD
3 Cross references
203 Possible Orthologues:

Protein Kinase C Delta Type-Like

Ensembl ID : ENSNBRG00000002170
Gene Symbol: LOC102786625
3 Cross references
204 Possible Orthologues:

Protein Kinase C Epsilon

Ensembl ID : ENSNBRG00000010716
Gene Symbol: PRKCE
3 Cross references
249 Possible Orthologues:

Protein Kinase C Epsilon

Ensembl ID : ENSNBRG00000008340
Gene Symbol: PRKCE
4 Cross references
246 Possible Orthologues:

Protein Kinase C Eta Type-Like

Ensembl ID : ENSNBRG00000009662
Gene Symbol: LOC102795342
3 Cross references
224 Possible Orthologues:

Protein Kinase C Iota Type-Like

Ensembl ID : ENSNBRG00000011552
Gene Symbol: LOC102783124
3 Cross references
87 Possible Orthologues:

Protein Kinase C Theta Type-Like

Ensembl ID : ENSNBRG00000012529
Gene Symbol: LOC102789446
3 Cross references
204 Possible Orthologues:

Protein Kinase C Zeta Type-Like

Ensembl ID : ENSNBRG00000004258
Gene Symbol: LOC102792715
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).